The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

AstraZeneca ( ($GB:AZN) ) has issued an announcement. AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

AstraZeneca has delivered on CEO Pascal Soriot’s promise to grow revenues to more than $40 billion by 2023. Now, the chief exec is already mapping out his next goal. AZ’s global revenue in 2022 ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche's drug, Perjeta, for the first-line treatment of patients with a type of ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space. The ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...